drugset
drugset / Trial / NCT06947304

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

NCT06947304 ↗

Phase 1 Recruiting 8 enrolled Corcept Therapeutics University of Missouri-Columbia · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Timeline

Start
2025-08-22
Primary completion
2026-05
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Miricorilant Small molecule 100 mg Oral

Indications

NAFLD1 metabolic dysfunction-associated steatohepatitis